BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
  Submission of the dossier 
The  applicant  Alcon  Laboratories  (U.K.)  Ltd.  submitted  on  22  April  2005  an  application  for 
Marketing  Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  DuoTrav,  through  the 
centralised procedure. 
The legal basis for this application refers to:  
Article 8.3 of Directive 2001/83/EC, as amended - complete and independent application 
Scientific Advice: 
The applicant did not seek scientific advice at the CHMP. 
Licensing status: 
The product was not licensed in any country at the time of submission of the application.  
A new application was filed in the following countries: USA (13/11/03), Australia (08/06/04), New 
Zealand (14/07/04). 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur: G. Calvo Rojas  
Co-Rapporteur: K. Broich 
2. 
  Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The application was received by the EMEA on 22 April 2005.  
The procedure started on 18 May 2005. 
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  5  August 
2005. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 29 
July 2005.  
During  the  meeting  on  13-15  September  2005,  the  CHMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 16 September 2005.  
The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on  16 
November 2005. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on 3 January 2006. 
During the CHMP meeting on 23-26 January 2006, the CHMP agreed on a list of outstanding 
issues to be addressed in writing and/or in an oral explanation by the applicant. 
The  applicant  submitted  the  responses  to  the  CHMP  list  of  outstanding  issues  on  30  January 
2006. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the list 
of outstanding issues to all CHMP members on 8 February 2006. 
During  the  meeting  on  20-23  February  2006,  the  CHMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
©EMEA 2006 
1/2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
granting a Marketing Authorisation to DuoTrav on 23 February 2006. The applicant provided 
the  letter  of  undertaking  on  the  follow-up  measures  to  be  fulfilled  post-authorisation  on  22 
February 2006. 
• 
The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 24 April 2006. 
©EMEA 2006 
2/2 
 
 
 
 
 
 
